

CLAIMS

1. Use of anifrolumab in the manufacture of a medicament for the treatment of systemic lupus erythematosus (SLE) in a subject in need thereof, wherein the anifrolumab is to be administered with a steroid to the subject, wherein the dose of the steroid to be administered to the subject is tapered from a pre-sparing dose at baseline to a post-sparing dose, wherein post-sparing dose is $\leq 50\%$ of the pre-sparing dose.
2. The use of claim 1, wherein the medicament does not worsen SLE disease activity in the subject.
3. The use of claim 1 or 2, wherein the post-sparing dose is $\leq 25\%$ of the pre-sparing dose.
4. The use of any preceding claim, wherein the post-sparing dose is $\leq 10\%$ of the pre-sparing dose.
5. Use of anifrolumab in the manufacture of a medicament for the treatment of SLE in a subject, wherein the anifrolumab is to be administered with a steroid to the subject, wherein the dose of the steroid to be administered to the subject is tapered from a pre-sparing dose at baseline to a post-sparing dose, wherein the post-sparing dose is ≤ 5 mg/day prednisone or prednisone-equivalent dose.
6. The use of claim 5, wherein the pre-sparing steroid dose is ≥ 10 mg/day prednisone or prednisone-equivalent dose.
7. The use of any preceding claim, wherein the post-sparing dose is maintained for ≥ 12 weeks.
8. The use of any preceding claim, wherein the post-sparing dose is about 0 mg/day prednisone or prednisone-equivalent dose.
9. The use of any preceding claim, wherein the post-sparing dose is sustained for at least 1 week.
10. The use of any preceding claim, wherein the steroid comprises a glucocorticoid, optionally wherein the steroid comprises an oral glucocorticoid.
11. The use of any preceding claims, wherein the steroid comprises hydrocortisone, mometasone, fluticasone, fluocinolone acetonide, fluocinolone, flurandrenolone acetonide, ciclesonide, budesonide, beclomethasone, deflazacort, flunisolide, beclomethasone dipropionate, betamethasone, betamethasone valerate, methylprednisolone, dexamethasone, prednisolone, cortisol, triamcinolone, clobetasol, clobetasol propionate, clobetasol butyrate, cortisone, corticosterone, clocortolone, dihydroxycortisone, alclometasone, amcinonide, diflucortolone valerate, flucortolone, fluprednidene, fluandrenolone, fluorometholone, halcinonide, halobetasol, desonide, diflorasone, flurandrenolide, fluocinonide, prednicarbate, desoximetasone, fluprednisolone, prednisone, azelastine, dexamethasone 21-phosphate, fludrocortisone, flumethasone, fluocinonide, halopredone, hydrocortisone 17-valerate,

hydrocortisone 17-butyrate, hydrocortisone 21-acetate, prednisolone, prednisolone 21-phosphate, clobetasol propionate, triamcinolone acetonide, or a mixture thereof.

12. The use of any preceding claim, wherein the steroid comprises prednisone.
13. The use of any preceding claim, wherein the anifrolumab is to be administered to the subject at a dose of 300-1000 mg every four weeks (Q4W).
14. The use of any preceding claim, wherein the anifrolumab is to be administered to the subject intravenously.
15. The use of any of claims 1 to 13, wherein the anifrolumab is to be administered to the subject subcutaneously.